AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11978683
Drug: NVP DPP728
RxNorm normalized name: NVP
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NVP DPP728 at 100 mg t.i.d. and 150 mg b.i.d.
Trial: 2871819
Drug: Diazepam (4.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (4.4 to 140 micrograms/kg, cumulative dose)
Trial: 30043330
Drug: G‐CSF +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF + plerixafor (GP arm)
Trial: 30043330
Drug: G‐CSF alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF alone (G arm)
Trial: 29145540
Drug: Metformin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1000 mg daily)
Trial: 27764050
Drug: Topiramate (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (100 mg daily)
Trial: 24632673
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human activated protein C (rh-APC) 24 mcg/kg/h for 4 days
Trial: 22572649
Drug: Erythromycin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (200 mg in 20 mL 0.9% saline)
Trial: 22572649
Drug: Placebo (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (20 mL 0.9% saline)
Trial: 8540714
Drug: Ceftazidime 25
RxNorm normalized name: ceftazidime 250 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 25 mg/kg once daily
Trial: 8540714
Drug: Ceftazidime 25
RxNorm normalized name: ceftazidime 250 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 25 mg/kg twice daily
Trial: 1786500
Drug: Pramiracetam sulphate
RxNorm normalized name: aniracetam
DrugBank: Pramiracetam (DB13247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramiracetam sulphate 400 mg TID
Trial: 13679688
Drug: Control (medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (medical treatment)
Trial: 19508900
Drug: Celecoxib (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (specific dosage and duration not mentioned)
Trial: 17348993
Drug: Comparative water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparative water spray
Trial: 2450441
Drug: Atracurium 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium 0.1 mg kg‐1
Trial: 2450441
Drug: Pancuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium 0.6 mg kg‐1
Trial: 29694816
Drug: Oral azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral azithromycin (approximately 20 mg per kilogram of body weight)
Trial: 18706905
Drug: 100 microg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 microg/day transdermal estradiol
Trial: 3882681
Drug: Fluoxetine 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 30 mg
Trial: 8199601
Drug: Fluoxetine 60
RxNorm normalized name: fluoxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 60 mg
Trial: 1359846
Drug: 500-mg daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500-mg daily dose of zidovudine
Trial: 1359846
Drug: 1500-mg daily
RxNorm normalized name: glecaprevir
DrugBank: Glecaprevir (DB13879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1500-mg daily dose of zidovudine
Trial: 1359846
Drug: Zidovudine (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine (both doses)
Trial: 3925770
Drug: Ciba transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciba transdermal nitroglycerin placebo patch
Trial: 3925770
Drug: Transdermal patches
RxNorm normalized name: MENTHOL 0.3 g in 100 TOPICAL PATCH [Aroamas Cot Nicotine Transdermal Patches]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal patches (Ciba, Key, Searle)
Trial: 22785499
Drug: Cell therapy
RxNorm normalized name: hRPE cell therapy
DrugBank: ASP-7317 (DB18549)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cell therapy group (n = 7; CABG and injection of bone marrow mononuclear cells (BMNCs) within MI areas)
Trial: 22785499
Drug: Cell therapy
RxNorm normalized name: hRPE cell therapy
DrugBank: ASP-7317 (DB18549)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cell therapy group (n = 7)
Trial: 20159906
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg/day for 8 weeks
Trial: 12749424
Drug: Subcutaneous (s.c.)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (s.c.) injection of 10,000 IU of hCG
Trial: 12749424
Drug: Intramuscular (i.m.)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (i.m.) injection of 10,000 IU of hCG
Trial: 8706443
Drug: 200 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 micrograms of misoprostol administered vaginally every 12 hours, up to four times
Trial: 8706443
Drug: 400 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 micrograms of misoprostol administered vaginally every 12 hours, up to four times
Trial: 6810736
Drug: Merck 20‐micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Merck 20‐micrograms hepatitis B virus (HBV) vaccine
Trial: 27071072
Drug: Hotspot-targeted interventions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hotspot-targeted interventions (larviciding, distribution of long-lasting insecticide-treated nets, indoor residual spraying, focal mass drug administration)
Trial: 22876835
Drug: Buprenorphine transdermal
RxNorm normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine transdermal therapeutic system (Bup‐TTS) 17.5 μg/h
Trial: 22876835
Drug: Buprenorphine transdermal
RxNorm normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine transdermal therapeutic system (Bup‐TTS) 35 μg/h
Trial: 22876835
Drug: Buprenorphine transdermal
RxNorm normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine transdermal therapeutic system (Bup‐TTS) 52.5 μg/h
Trial: 22876835
Drug: Buprenorphine transdermal
RxNorm normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine transdermal therapeutic system (Bup‐TTS)
Trial: 21133003
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin injection and pneumatic dilation (BT+PD)
Trial: 17715139
Drug: Ondansetron 0.1
RxNorm normalized name: ONDANSETRON 0.16MG/ML D5W INJ BAG 50ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 0.1 mg kg(‐1)
Trial: 17715139
Drug: Metoclopramide 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 0.5 mg kg(‐1)
Trial: 15253175
Drug: Support received
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Support received during diagnosis and treatment
Trial: 11684527
Drug: CP‐DC diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP‐DC diet (22 g cocoa powder and 16 g dark chocolate)
Trial: 8070499
Drug: Ibuprofen syrup
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen syrup
Trial: 7926968
Drug: Phorbol myristate
RxNorm normalized name: Phorbol myristate acetate
DrugBank: Phorbol 12-myristate 13-acetate diester (DB17045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phorbol myristate acetate (PMA) treatment
Trial: 2478048
Drug: Midazolam (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (5 mg im)
Trial: 2478048
Drug: Oxymorphone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymorphone (1 mg iv)
Trial: 28059869
Drug: Longitudinal supra‐inguinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longitudinal supra‐inguinal fascia iliaca compartment block with 40‐mL ropivacaine 0.5%
Trial: 23689115
Drug: Panretinal photocoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panretinal photocoagulation (PRP) plus intravitreal bevacizumab (IVB) injections
Trial: 15134316
Drug: 15‐min single‐dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15‐min single‐dose brief intervention
Trial: 11375808
Drug: Milrinone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milrinone (50 micro/kg) administered through the bypass pump 10 min before aortic cross-clamping
Trial: 9404430
Drug: Antihypertensive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive therapy (specifics not provided)
Trial: 8495453
Drug: Diclofenac-K 50
RxNorm normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac-K 50 mg
Trial: 8495453
Drug: Diclofenac-K 100
RxNorm normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac-K 100 mg
Trial: 30844477
Drug: Ginger supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger supplementation (1500 mg daily for 12 weeks)
Trial: 11736876
Drug: Oral artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral artesunate (4 mg kg(‐1))
Trial: 11736876
Drug: Oral artemether
RxNorm normalized name: Artemether
DrugBank: Artemether (DB06697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral artemether (4 mg kg(‐1))
Trial: 11736876
Drug: Oral artemether
RxNorm normalized name: Artemether
DrugBank: Artemether (DB06697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral artemether (first day of treatment)
Trial: 11736876
Drug: Oral artemether
RxNorm normalized name: Artemether
DrugBank: Artemether (DB06697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral artemether (second day of treatment)
Trial: 11736876
Drug: In vivo
RxNorm normalized name: IMAGING AGENTS (IN VIVO) RADIOPHARMACEUTICALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vivo parasite clearance and time above the in vitro IC90 for both drugs
Trial: 28598116
Drug: LE+CC
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LE+CC
Trial: 28598116
Drug: CC+HMG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC+HMG
Trial: 28598116
Drug: LE+CC+HMG
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LE+CC+HMG
Trial: 11464141
Drug: Protease Inhibitor
RxNorm normalized name: Protease inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease Inhibitor (Group B)
Trial: 9552778
Drug: bupivacaine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine + both (i.t. 10 mg bupivacaine + 50 microg neostigmine + 150 microg clonidine)
Trial: 9552778
Drug: bupivacaine (i.t.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine (i.t. 10 mg bupivacaine)
Trial: 9552778
Drug: bupivacaine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine + neostigmine (i.t. 10 mg bupivacaine + 50 microg neostigmine)
Trial: 9552778
Drug: bupivacaine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine + clonidine (i.t. 10 mg bupivacaine + 150 microg clonidine)
Trial: 7868704
Drug: Matched controls
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched controls from the Child Health Supplement of the National Health Interview Survey (CHS88)
Trial: 3421598
Drug: Relapse Prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relapse Prevention treatment
Trial: 7263877
Drug: No-treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment group (control)
Trial: 28851065
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 270 μg kg‐1 rFVIIa
Trial: 28851065
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of 3×90 μg kg‐1 rFVIIa
Trial: 25285748
Drug: Cardiac contractility
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac contractility modulation (CCM) plus optimal medical therapy (OMT)
Trial: 25285748
Drug: Cardiac contractility
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac contractility modulation (CCM) plus optimal medical therapy (OMT) in patients with EFs ranging from 25% to 45%
Trial: 22949122
Drug: Dexamethasone +
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone + Ibuprofen
Trial: 21448073
Drug: Dexketoprofen (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexketoprofen (50 mg) intravenously
Trial: 21448073
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 mL of 0.9% NaCL) intravenously
Trial: 12830447
Drug: Home hemodialysis
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home hemodialysis (HD) with the Fresenius 2008H machine and Service Deionization Tank (SDI) water treatment system
Trial: 10854552
Drug: Cisplatin-based cyclic
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based cyclic balloon-occluded arterial infusion chemotherapy (BOAI)
Trial: 8464671
Drug: Cromolyn sodium
RxNorm normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cromolyn sodium (20 mg) aerosolized every 6 hours starting on the first day of intubation
Trial: 31268250
Drug: GSK256073 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK256073 5 mg/day
Trial: 31268250
Drug: GSK256073 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK256073 50 mg/day
Trial: 31268250
Drug: GSK256073 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK256073 150 mg/day
Trial: 23091096
Drug: Intensified treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified treatment (chemotherapy every 14 days)
Trial: 23091096
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (chemotherapy every 21 days)
Trial: 17997459
Drug: Epirubicin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin (50 mg instillation)
Trial: 10036609
Drug: 0.62 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.62 g/kg alcohol
Trial: 19278796
Drug: 0.8 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 g/kg alcohol
Trial: 24519012
Drug: Placebo (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0 g/kg)
Trial: 1281362
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH; Sandoparin) administered once daily subcutaneously at a fixed dosage
Trial: 1281362
Drug: Dextran 70
RxNorm normalized name: Dextran 70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextran 70 administered intravenously
Trial: 1281362
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) and Dextran 70
Trial: 31533277
Drug: 15 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 µg dose of VLP vaccine
Trial: 31533277
Drug: 45 µg
RxNorm normalized name: tazarotene
DrugBank: Tazarotene (DB00799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 45 µg dose of VLP vaccine
Trial: 25580784
Drug: Topical betamethasone
RxNorm normalized name: betamethasone Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical betamethasone for RAS (Control)
Trial: 22226929
Drug: firategrast 900
RxNorm normalized name: Firategrast
DrugBank: Firategrast (DB12732)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: firategrast 900 mg or 1200 mg
Trial: 22226929
Drug: firategrast 600
RxNorm normalized name: Firategrast
DrugBank: Firategrast (DB12732)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: firategrast 600 mg
Trial: 22226929
Drug: firategrast 150
RxNorm normalized name: Firategrast
DrugBank: Firategrast (DB12732)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: firategrast 150 mg
Trial: 15889358
Drug: Amoxicillin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (1000 mg 3 times per day) for patients with positive urinary antigen test results
Trial: 15889358
Drug: Clarithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (500 mg 2 times per day) for patients with negative urinary antigen test results
Trial: 12479768
Drug: Standardized HRQL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized HRQL assessments (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire‐Core 30)
Trial: 8592955
Drug: Thiazide diuretic
RxNorm normalized name: Thiazide diuretic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiazide diuretic use
Trial: 2696507
Drug: IV labetalol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV labetalol, 0.25 mg/kg
Trial: 2696507
Drug: IV labetalol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV labetalol, 0.75 mg/kg
Trial: 18493
Drug: 30 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/day clobazam (HR 376)
Trial: 18493
Drug: 15 mg/day
RxNorm normalized name: Climara Pro 0.045/0.015 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/day diazepam
Trial: 19387874
Drug: Lifestyle intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lifestyle intervention + Metformin (1500 g daily)
Trial: 16711496
Drug: Continuous sciatic
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous sciatic nerve block (0.5% ropivacaine, 20 mL, plus continuous infusion of 5 mL/h)
Trial: 16711496
Drug: Single-dose sciatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose sciatic nerve block (20 mL of 0.5% ropivacaine)
Trial: 14709300
Drug: Topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac sodium 0.1% solution (Voltaren Ophthalmic)
Trial: 14709300
Drug: Topical ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ketorolac tromethamine 0.5% solution (Acular)
Trial: 9036608
Drug: EHF therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EHF therapy alone (group 1)
Trial: 9036608
Drug: EHF therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EHF therapy plus antibacterial drugs (group 2)
Trial: 3979723
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g protein meal
Trial: 3979723
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g protein meal
Trial: 31102823
Drug: Antibiotic lock
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic lock solution (gentamicin 7 mg/ml + cefazolin 12 mg/ml + heparin 3500 IU/ml)
Trial: 31102823
Drug: Lock solution
RxNorm normalized name: Defencath catheter lock solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lock solution with TauroLock-Hep500 (taurolidine citrate 4% + heparin 500 IU/ml)
Trial: 29534661
Drug: Bortezomib (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib (1 cycle at 1.3 mg/m2), methylprednisolone (500 mg/kg), 7 sessions of plasmapheresis, antithymocyte globulin (3-5 mg/kg/day for 10 days), rituximab (2 doses at 375 mg/m2)
Trial: 29534661
Drug: Bortezomib-based treatment
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib-based treatment
Trial: 26814104
Drug: Dexmedetomidine 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.4 µg·kg(‐1)·h(‐1)
Trial: 26814104
Drug: Dexmedetomidine 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.6 µg·kg(‐1)·h(‐1)
Trial: 26814104
Drug: Dexmedetomidine 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.8 µg·kg(‐1)·h(‐1)
Trial: 26814104
Drug: Dexmedetomidine 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1.0 µg·kg(‐1)·h(‐1)
Trial: 26814104
Drug: Remifentanil 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 0.1 µg·kg(‐1)·min(‐1)
Trial: 26814104
Drug: Dexmedetomidine 0.6-1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.6-1.0 µg·kg(‐1)·h(‐1)
Trial: 26814104
Drug: Dexmedetomidine 0.4-0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.4-0.8 µg·kg(‐1)·h(‐1)
Trial: 21680720
Drug: Autologous dendritic
RxNorm normalized name: COVID19 s-vax loaded autologous dendritic cell vaccine
DrugBank: COVID19 s-vax loaded autologous dendritic cell vaccine (DB15814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous dendritic cells administered intradermally (10 million cells, once every 2 weeks for 4 administrations)
Trial: 12669389
Drug: Treatment methods
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment methods from randomized trials
Trial: 12669389
Drug: Evidence-based medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based medicine
Trial: 11595472
Drug: OCT (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCT (20 mg omeprazole + 2 x 250 mg clarithromycin + 2 x 500 mg tinidazole for 7 days)
Trial: 11595472
Drug: OAM (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAM (20 mg omeprazole + 2 x 1000 mg amoxicillin + 2 x 500 mg metronidazole for 7 days)
Trial: 11595472
Drug: PAC (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAC (40 mg pantoprazole + 2 x 1000 mg amoxicillin + 2 x 500 mg clarithromycin for 7 days)